Compare ยท nothing stored
Treatment Comparison
Injections, gel, oral, pellets or nasal, side by side on the things that differ.
Everything you enter stays in this browser. Nothing is sent to a server.
Pick two or more to compare
| Injections | Gels and creams | Oral capsules | Pellets | Nasal gel | |
|---|---|---|---|---|---|
| What it is | Cypionate or enanthate in oil, intramuscular or subcutaneous; long-acting undecanoate in clinic | Daily gel (brand or generic) or compounded cream to shoulders, arms or abdomen | Testosterone undecanoate capsules (several US brands), taken with food | Crystalline pellets implanted under the skin of the hip or buttock in a minor office procedure | Metered nasal gel |
| Dosing frequency | Weekly or twice weekly is common; undecanoate every 10 weeks after loading | Every day, same time | Twice daily with meals | Every 3 to 6 months | Two or three times daily |
| Level stability | Peak after injection, trough before the next; shorter intervals flatten it | Steady day to day if applied consistently; absorption varies between people | Rises and falls within the day; fat in the meal affects absorption | High early, declining toward the next implant; dose cannot be adjusted once placed | Short-acting; levels pulse with each dose |
| Self-administered | Yes for cypionate and enanthate after training; undecanoate is clinic-administered | Yes | Yes | No | Yes |
| Transfer risk to others | None | Yes; skin contact can transfer testosterone to partners or children until dry and covered | None | None | None |
| Fertility impact | Suppresses LH and FSH, so sperm production falls; hCG is often paired for men who want fertility | Same suppression of LH and FSH as any external testosterone | Same suppression as other forms | Same suppression as other forms | Reported to suppress LH and FSH less than longer-acting forms in small studies; not a fertility treatment |
| Monitoring notes | Hematocrit tends to rise more than with transdermals; standard labs otherwise | Timing of the blood draw relative to application matters for interpreting levels | Blood pressure monitoring is specifically called for in the US labelling; draw timing after a dose matters | Standard labs; extrusion or infection at the site is the procedure-specific risk | Nasal irritation and congestion are the specific issues |
| Cost | Lowest medication cost for generics; see the cost estimator | Generic gel moderate; brand gels high; see the cost estimator | High; brand only; see the cost estimator | Procedure fee each time; see the cost estimator | High; brand only; see the cost estimator |
| Trade-off in one line | Most widely used and most studied; needling and disposal are the practical cost | Daily habit and transfer precautions are the trade-offs for stable levels | No needles, no transfer risk; cost and twice-daily dosing with food are the trade-offs | Convenience between implants, with no way to lower a dose until the pellet is spent | Frequent dosing is the practical cost of its short action |
Descriptive comparison from guideline and labelling sources listed below. Not a recommendation. Each column header links to the full entry.
How to Read the Table
Every row is something that genuinely differs between methods. Rows where every method is the same (the diagnosis required, the labs drawn, the fact that all forms suppress fertility) are either collapsed into one line or left out, so the grid shows decisions rather than repetition.
Two rows deliberately point elsewhere. Cost goes to the estimator because a cash price for generic cypionate and a brand oral capsule can differ by an order of magnitude. Level stability is described in words because the shape depends on the interval you choose, which the injection planner lets you set.
Frequently Asked Questions
Which method is best?
Why are there no numbers in the table?
Do all methods affect fertility?
Can I switch methods later?
Sources
- Bhasin S et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744
- Mulhall JP et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432
- US FDA, Testosterone Information (class labelling, including blood pressure warnings for oral products)
- DailyMed prescribing information for testosterone products